Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CISPLATIN Cause Bladder cancer recurrent? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Bladder cancer recurrent have been filed in association with CISPLATIN (CISplatin). This represents 0.0% of all adverse event reports for CISPLATIN.

7
Reports of Bladder cancer recurrent with CISPLATIN
0.0%
of all CISPLATIN reports
1
Deaths
1
Hospitalizations

How Dangerous Is Bladder cancer recurrent From CISPLATIN?

Of the 7 reports, 1 (14.3%) resulted in death, 1 (14.3%) required hospitalization.

Is Bladder cancer recurrent Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CISPLATIN. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does CISPLATIN Cause?

Off label use (4,359) Disease progression (3,746) Neutropenia (3,095) Febrile neutropenia (3,010) Nausea (2,923) Drug ineffective (2,608) Thrombocytopenia (2,565) Anaemia (2,530) Vomiting (2,326) Diarrhoea (2,022)

What Other Drugs Cause Bladder cancer recurrent?

BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (231) PIOGLITAZONE (130) RANITIDINE (66) BACILLUS CALMETTE-GUERIN ANTIGEN, UNSPECIFIED SUBSTRAIN (28) MITOMYCIN (20) PEMBROLIZUMAB (20) ADALIMUMAB (19) GEMCITABINE\GEMCITABINE (19) METHOTREXATE (16) GEMCITABINE (15)

Which CISPLATIN Alternatives Have Lower Bladder cancer recurrent Risk?

CISPLATIN vs CISPLATIN\CYTARABINE\DEXAMETHASONE CISPLATIN vs CITALOPRAM CISPLATIN vs CITALOPRAM HYDROBROMIDE CISPLATIN vs CITALOPRAM\CITALOPRAM HYDROBROMIDE CISPLATIN vs CITICOLINE

Related Pages

CISPLATIN Full Profile All Bladder cancer recurrent Reports All Drugs Causing Bladder cancer recurrent CISPLATIN Demographics